Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cagrilintide/semaglutide - Novo Nordisk

Drug Profile

Cagrilintide/semaglutide - Novo Nordisk

Alternative Names: CagriSema; NN-9388

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Amylin receptor agonists; Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Obesity; Type 2 diabetes mellitus
  • Phase II Renal failure

Most Recent Events

  • 06 May 2024 Novo Nordisk plans a phase I trial for Type II Diabetes mellitus in Germany (SC) in May2024 (NCT06403761) (EudraCT2023-509483-20)
  • 29 Apr 2024 Novo Nordisk plans a phase III trial for Obesity in United Kingdom, USA, Germany, France and Canada (SC) (NCT06388187)
  • 01 Apr 2024 Phase-II clinical trials in Obesity (Treatment-experienced) in USA, Canada, Japan (SC) (NCT06131372)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top